Cargando…

Perplexing issues for convalescent immune plasma therapy in COVID-19

Convalescent immune plasma (CIP) therapy in coronavirus disease 2019 (COVID-19) is presently a trendy choice of treatment. On March 24, 2020, the United States Food and Drug Administration approved of CIP treatment for seriously ill COVID-19 patients as an emergency investigational new drug. The pre...

Descripción completa

Detalles Bibliográficos
Autor principal: Ozdemir, Oner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Health Directorate of Istanbul 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848483/
https://www.ncbi.nlm.nih.gov/pubmed/35284793
http://dx.doi.org/10.14744/nci.2021.73604

Ejemplares similares